Co-Trimoxazole in Wegener's Granulomatosis

To the Editor: In their study of treatment with co-trimoxazole (trimethoprim–sulfamethoxazole) to prevent relapses of Wegener's granulomatosis (July 4 issue), 1 Stegeman et al. do not report the cumulative doses of cyclophosphamide and prednisolone in their two groups of patients during the stu...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 1996-12, Vol.335 (23), p.1769-1770
Hauptverfasser: Weir, A, Lipman, M, Congleton, J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To the Editor: In their study of treatment with co-trimoxazole (trimethoprim–sulfamethoxazole) to prevent relapses of Wegener's granulomatosis (July 4 issue), 1 Stegeman et al. do not report the cumulative doses of cyclophosphamide and prednisolone in their two groups of patients during the study period. Although this omission does not undermine their conclusion, it is relevant because the information may shed light on the mechanism by which co-trimoxazole prevents relapses. If, as Stegeman et al. speculate, co-trimoxazole either prevents infections that would have triggered relapses or has a direct antiinflammatory effect, then one would expect a lower cumulative dose of immunosuppressive agents . . .
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJM199612053352314